000163053 001__ 163053
000163053 005__ 20240229123147.0
000163053 0247_ $$2doi$$a10.3390/cancers12092537
000163053 0247_ $$2pmid$$apmid:32906608
000163053 0247_ $$2altmetric$$aaltmetric:89941920
000163053 037__ $$aDKFZ-2020-01839
000163053 041__ $$aeng
000163053 082__ $$a610
000163053 1001_ $$0P:(DE-He78)e7c860fe438c12cbe5f071b3f86d5738$$aWennmann, Markus$$b0$$eFirst author$$udkfz
000163053 245__ $$aSpatial Distribution of Focal Lesions in Whole-Body MRI and Influence of MRI Protocol on Staging in Patients with Smoldering Multiple Myeloma According to the New SLiM-CRAB-Criteria.
000163053 260__ $$aBasel$$bMDPI$$c2020
000163053 3367_ $$2DRIVER$$aarticle
000163053 3367_ $$2DataCite$$aOutput Types/Journal article
000163053 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1603092149_20926
000163053 3367_ $$2BibTeX$$aARTICLE
000163053 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000163053 3367_ $$00$$2EndNote$$aJournal Article
000163053 500__ $$a#EA:E010#
000163053 520__ $$aThe purpose of this study was to assess how different MRI protocols (spinal vs. spinal plus pelvic vs. whole-body (wb)-MRI) affect staging in patients with smoldering multiple myeloma (SMM), according to the SLiM-CRAB-criterion '>1 focal lesion (FL) in MRI'. In this retrospective study, a baseline cohort of 147 SMM patients with wb-MRI at initial diagnosis was investigated, including prognostic data regarding development of CRAB-criteria. Fifty-two patients formed a follow-up cohort with a median of three wb-MRIs. The locations of all FLs were determined and it was calculated how staging decisions regarding the criterion '>1 FL in MRI' would have been made if only a limited anatomic area (spine vs. spine plus pelvis) would have been covered by the MRI protocol. Furthermore, subgroups of patients selected by different cutoff-protocol-combinations were compared regarding their prognosis for development of CRAB-criteria. With an MRI protocol limited to spine/spine plus pelvis, only 28%/64% of patients who actually had >1 FL in wb-MRI would have been rated correctly as having '>1 FL in MRI'. Fifty-four percent/36% of patients with exactly 1 FL in spine/spine plus pelvis revealed >1 FL when the entire wb-MRI was analyzed. During follow-up, four more patients developed >1 FL in wb-MRI; both limited MRI protocols would have detected only one of these four patients as having >1 FL at the correct timepoint. Having >1 FL in spine/in spine plus pelvis/in the whole body was associated with a 43%/57%/49% probability of developing CRAB-criteria within 2 years. Patients with >3 FL in spine plus pelvis and patients with >4 FL in the whole body had an 80% probability to develop CRAB-criteria within 2 years. MRI protocols limited to the spine or to spine plus pelvis lead to substantial underdiagnoses of patients who actually have >1 FL in wb-MRI at baseline and during follow-up, which influences staging and treatment decisions according to the current SLiM-CRAB criteria. However, given the spatial distribution of FLs and the analysis on clinical course of patients indicates that the cutoff for the number of FLs should be adopted according to the MRI protocol when using MRI for staging in SMM.
000163053 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000163053 588__ $$aDataset connected to CrossRef, PubMed,
000163053 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b1$$udkfz
000163053 7001_ $$aKintzelé, Laurent$$b2
000163053 7001_ $$aMenze, Bjoern H$$b3
000163053 7001_ $$aLangs, Georg$$b4
000163053 7001_ $$aMerz, Maximilian$$b5
000163053 7001_ $$aSauer, Sandra$$b6
000163053 7001_ $$aKauczor, Hans-Ulrich$$b7
000163053 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b8$$udkfz
000163053 7001_ $$0P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDelorme, Stefan$$b9$$udkfz
000163053 7001_ $$aGoldschmidt, Hartmut$$b10
000163053 7001_ $$aWeinhold, Niels$$b11
000163053 7001_ $$aHillengass, Jens$$b12
000163053 7001_ $$aWeber, Marc-André$$b13
000163053 773__ $$0PERI:(DE-600)2527080-1$$a10.3390/cancers12092537$$gVol. 12, no. 9, p. 2537 -$$n9$$p2537$$tCancers$$v12$$x2072-6694$$y2020
000163053 909CO $$ooai:inrepo02.dkfz.de:163053$$pVDB
000163053 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e7c860fe438c12cbe5f071b3f86d5738$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000163053 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000163053 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000163053 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3e76653311420a51a5faeb80363bd73e$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000163053 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000163053 9141_ $$y2020
000163053 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCERS : 2018$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2019-12-21
000163053 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCERS : 2018$$d2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$f2019-12-21
000163053 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2019-12-21
000163053 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lE010 Radiologie$$x0
000163053 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lC060 Biostatistik$$x1
000163053 980__ $$ajournal
000163053 980__ $$aVDB
000163053 980__ $$aI:(DE-He78)E010-20160331
000163053 980__ $$aI:(DE-He78)C060-20160331
000163053 980__ $$aUNRESTRICTED